Naz Faiza, Tariq Imran, Ali Sajid, Somaida Ahmed, Preis Eduard, Bakowsky Udo
Punjab University College of Pharmacy, Allama Iqbal Campus, University of the Punjab, Lahore 54000, Pakistan.
Department of Pharmaceutics and Biopharmaceutics, University of Marburg, Robert-Koch-Str. 4, 35037 Marburg, Germany.
Cancers (Basel). 2021 Dec 3;13(23):6102. doi: 10.3390/cancers13236102.
Recent advances in molecular biology have discovered the mysterious role of long non-coding RNAs (lncRNAs) as potential biomarkers for cancer diagnosis and targets for advanced cancer therapy. Studies have shown that lncRNAs take part in the incidence and development of cancers in humans. However, previously they were considered as mere RNA noise or transcription byproducts lacking any biological function. In this article, we present a summary of the progress on ascertaining the biological functions of five lncRNAs (HOTAIR, NEAT1, H19, MALAT1, and MEG3) in female-oriented cancers, including breast and gynecological cancers, with the perspective of carcinogenesis, cancer proliferation, and metastasis. We provide the current state of knowledge from the past five years of the literature to discuss the clinical importance of such lncRNAs as therapeutic targets or early diagnostic biomarkers. We reviewed the consequences, either oncogenic or tumor-suppressing features, of their aberrant expression in female-oriented cancers. We tried to explain the established mechanism by which they regulate cancer proliferation and metastasis by competing with miRNAs and other mechanisms involved via regulating genes and signaling pathways. In addition, we revealed the association between stated lncRNAs and chemo-resistance or radio-resistance and their potential clinical applications and future perspectives.
分子生物学的最新进展发现了长链非编码RNA(lncRNAs)作为癌症诊断潜在生物标志物和晚期癌症治疗靶点的神秘作用。研究表明,lncRNAs参与人类癌症的发生和发展。然而,以前它们被认为仅仅是RNA噪音或缺乏任何生物学功能的转录副产物。在本文中,我们从致癌作用、癌症增殖和转移的角度,总结了五种lncRNAs(HOTAIR、NEAT1、H19、MALAT1和MEG3)在女性相关癌症(包括乳腺癌和妇科癌症)中生物学功能确定方面的进展。我们提供了过去五年文献中的现有知识状态,以讨论此类lncRNAs作为治疗靶点或早期诊断生物标志物的临床重要性。我们回顾了它们在女性相关癌症中异常表达的致癌或抑癌特征的后果。我们试图解释它们通过与微小RNA竞争以及通过调节基因和信号通路涉及的其他机制来调节癌症增殖和转移的既定机制。此外,我们揭示了所述lncRNAs与化疗耐药性或放疗耐药性之间的关联及其潜在的临床应用和未来前景。